+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating how well guselkumab works compared to risankizumab in people with moderately to severely active Crohns Disease, a long-term condition causing severe inflammation in the intestines. This Phase 3b study aims to compare the effectiveness and safety of these two treatments to better understand their impact on this condition. Participants will receive either guselkumab or risankizumab following specific dosing schedules. Those receiving guselkumab will get induction doses by subcutaneous injection at Weeks 0, 4, and 8, then maintenance doses every 4 weeks from Week 12 through Week 52. Participants in the risankizumab group will receive induction doses intravenously at Weeks 0, 4, and 8, followed by maintenance doses by subcutaneous injection every 8 weeks from Week 12 to Week 52. During the study, participants will be monitored for deep remission at Week 52, along with other outcomes like clinical remission, endoscopic response, and steroid-free remission. Safety will be assessed by tracking adverse events and lab test abnormalities up to Week 165. Follow-up will continue to evaluate long-term effects, with participant involvement lasting until study completion in 2030.

Age: 18Years +All GendersPhase 3
164 locations
S

Actively Recruiting

Researchers are evaluating whether combining mirikizumab with tirzepatide can reduce or eliminate symptoms of moderately to severely active ulcerative colitis UC and help participants lose at least 10% of their body weight. This phase 3b study focuses on adults with UC who are also obese or overweight, comparing treatment with mirikizumab plus tirzepatide against mirikizumab plus placebo. The study is sponsored by Eli Lilly and Company and aims to better understand treatment effects on UC symptoms and weight loss. Participants receive mirikizumab first by intravenous infusion, followed by subcutaneous injections of mirikizumab. They are randomly assigned to also receive either tirzepatide or a placebo via subcutaneous injection. Treatment lasts up to 52 weeks. The study is double-blinded, so neither participants nor researchers know who receives tirzepatide or placebo during the trial. Throughout the study, participants undergo regular monitoring including clinical assessments to evaluate remission and response of UC symptoms, endoscopic exams, and histologic evaluations. Researchers measure the percentage of participants who achieve both clinical remission and significant weight loss at week 52. The total participation time is up to 61 weeks, including screening and treatment. Safety and effectiveness are closely tracked during and after treatment.

Age: 18Years - 70YearsAll GendersPhase 3
186 locations
S

Actively Recruiting

This trial investigates the safety and effectiveness of mirikizumab combined with tirzepatide versus mirikizumab with placebo in adults who have moderately to severely active Crohns disease along with obesity or overweight. The study is a phase 3b clinical trial and aims to assess how well these treatments work together to improve disease activity and reduce weight. Participants are randomly assigned to one of two groups one receives mirikizumab intravenously followed by subcutaneous administration along with tirzepatide given subcutaneously the other group receives mirikizumab in the same way but with a placebo injection instead of tirzepatide. Treatments are given according to a defined schedule over the course of the study, which lasts up to 61 weeks. Throughout the trial, participants undergo regular monitoring including clinical assessments for Crohns disease activity, endoscopic evaluations, and measurements of body weight. Researchers track outcomes like clinical remission, endoscopic remission, and weight loss at various time points, especially at Week 52. Safety and tolerability are also carefully observed during the study period that may extend up to 61 weeks.

Age: 18Years - 70YearsAll GendersPhase 3
183 locations